Ascletis Pharma Inc
HKEX:1672
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.78
1.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ascletis Pharma Inc
Ascletis Pharma Inc
Other Current Liabilities
Ascletis Pharma Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascletis Pharma Inc
HKEX:1672
|
Other Current Liabilities
¥44.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Other Current Liabilities
¥1.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Other Current Liabilities
¥465.9m
|
CAGR 3-Years
333%
|
CAGR 5-Years
148%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Other Current Liabilities
¥1.9B
|
CAGR 3-Years
53%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Other Current Liabilities
¥343.5m
|
CAGR 3-Years
27%
|
CAGR 5-Years
12%
|
CAGR 10-Years
27%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Other Current Liabilities
¥2.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
55%
|
CAGR 10-Years
58%
|
|
Ascletis Pharma Inc
Glance View
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
See Also
What is Ascletis Pharma Inc's Other Current Liabilities?
Other Current Liabilities
44.2m
CNY
Based on the financial report for Dec 31, 2023, Ascletis Pharma Inc's Other Current Liabilities amounts to 44.2m CNY.
What is Ascletis Pharma Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-1%
Over the last year, the Other Current Liabilities growth was -8%. The average annual Other Current Liabilities growth rates for Ascletis Pharma Inc have been 3% over the past three years , -1% over the past five years .
You don't have any saved screeners yet
